- Home
- BCYC vs ORKA Comparison
BCYC vs ORKA Comparison
Compare BCYC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- ORKA
- Stock Information
- Founded
- BCYC 2009
- ORKA 2004
- Country
- BCYC United Kingdom
- ORKA United States
- Employees
- BCYC N/A
- ORKA N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BCYC Health Care
- ORKA Health Care
- Exchange
- BCYC Nasdaq
- ORKA Nasdaq
- Market Cap
- BCYC 492.1M
- ORKA 580.3M
- IPO Year
- BCYC 2019
- ORKA N/A
- Fundamental
- Price
- BCYC $6.93
- ORKA $15.55
- Analyst Decision
- BCYC Buy
- ORKA Strong Buy
- Analyst Count
- BCYC 11
- ORKA 7
- Target Price
- BCYC $22.91
- ORKA $43.00
- AVG Volume (30 Days)
- BCYC 231.1K
- ORKA 252.5K
- Earning Date
- BCYC 10-30-2025
- ORKA 11-12-2025
- Dividend Yield
- BCYC N/A
- ORKA N/A
- EPS Growth
- BCYC N/A
- ORKA N/A
- EPS
- BCYC N/A
- ORKA N/A
- Revenue
- BCYC $19,281,000.00
- ORKA N/A
- Revenue This Year
- BCYC N/A
- ORKA N/A
- Revenue Next Year
- BCYC N/A
- ORKA N/A
- P/E Ratio
- BCYC N/A
- ORKA N/A
- Revenue Growth
- BCYC N/A
- ORKA N/A
- 52 Week Low
- BCYC $6.10
- ORKA $5.49
- 52 Week High
- BCYC $28.67
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- BCYC 43.13
- ORKA 51.81
- Support Level
- BCYC $6.77
- ORKA $14.67
- Resistance Level
- BCYC $7.32
- ORKA $18.50
- Average True Range (ATR)
- BCYC 0.38
- ORKA 1.16
- MACD
- BCYC 0.02
- ORKA -0.02
- Stochastic Oscillator
- BCYC 20.16
- ORKA 22.98
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.